News
Shares of INmune Bio climbed after the biotech company said its trial for treatment of a certain prostate cancer met its targets. The stock was up 11%, to $2.83, but is still down 65% over the ...
2d
InvestorsHub on MSNINmune Bio Shares Surge as Prostate Cancer Trial Achieves Key Goals
INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...
INmune Bio Inc. (NASDAQ: INMB) (the 'Company'), a clinical-stage immunology and inflammation company, is pleased to report ...
Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...
Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...
INKmune® is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to convert the cancer ...
INKmune™ is treating patients in an open label Phase I/II trial in metastatic castration-resistant prostate cancer in the US. About INmune Bio Inc. (INMB) ...
“INKmune™ can be given to men with mCRPC in an out-patient setting and so far has an exemplary safety profile,” said RJ Tesi, MD CEO of INmune. “Data from the low dose cohort has shown ...
INKmune™ is tumor agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer.
INKmune™ is a patented, pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals, akin to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results